UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

Annals of oncology, 2018-01, Vol.29 (suppl_1), p.i10-i19

2018

Volltextzugriff (PDF)

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

Annals of oncology, 2021-12, Vol.32 (12), p.1597-1607

2021

Volltextzugriff (PDF)

Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib

Lung cancer (Amsterdam, Netherlands), 2017-09, Vol.111, p.84-87

2017

Volltextzugriff (PDF)

APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas

Annals of oncology, 2022-12, Vol.33 (12), p.1284-1295

2022

Volltextzugriff (PDF)

Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC)

Annals of oncology, 2019-04, Vol.30, p.ii48-ii48

2019

Volltextzugriff (PDF)

Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding

Oncogene, 2001-04, Vol.20 (15), p.1839-1851

2001

Volltextzugriff (PDF)

112OCirculating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC)

Annals of oncology, 2019-04, Vol.30 (Supplement_2)

2019

Volltextzugriff (PDF)

Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation

Molecular cancer research, 2003-06, Vol.1 (8), p.598-609

2003

Volltextzugriff (PDF)

DIRECT: DNA-mutation Inventory to Refine and Enhance Cancer Treatment—A catalogue of clinically relevant somatic mutations in lung cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.7575-7575

2011

Volltextzugriff (PDF)

My Cancer Genome: Web-based clinical decision support for genome-directed lung cancer treatment

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.7576-7576

2011

Volltextzugriff (PDF)

Characterization of novel potent and selective anaplastic lymphoma kinase (ALK) inhibitors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e13600-e13600

2011

Volltextzugriff (PDF)

Abstract P3-03-03: An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P3-P3-03-03

2017

Volltextzugriff (PDF)

Accurate Mass-Driven Analysis for the Characterization of Protein Phosphorylation. Study of the Human Chk2 Protein Kinase

Analytical chemistry (Washington), 2006-04, Vol.78 (7), p.2171-2181

2006

Volltextzugriff (PDF)

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials

PloS one, 2012-04, Vol.7 (4), p.e35309-e35309

2012

Volltextzugriff (PDF)

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

Nature communications, 2016-01, Vol.7 (1), p.10582-10582, Article 10582

2016

Volltextzugriff (PDF)

Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions

Cancer discovery, 2014-08, Vol.4 (8), p.889-895

2014

Volltextzugriff (PDF)

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

Cancer immunology research, 2016-11, Vol.4 (11), p.959-967

2016

Volltextzugriff (PDF)

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Clinical cancer research, 2012-09, Vol.18 (17), p.4682-4690

2012

Volltextzugriff (PDF)

Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids

Nature communications, 2014-03, Vol.5 (1), p.3518-3518, Article 3518

2014

Volltextzugriff (PDF)

EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer

Cancer research (Chicago, Ill.), 2016-01, Vol.76 (2), p.305-318

2016

Volltextzugriff (PDF)

Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting

Nature communications, 2021-03, Vol.12 (1), p.1382-15, Article 1382

2021

Volltextzugriff (PDF)

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

Cancer discovery, 2013-04, Vol.3 (4), p.430-443

2013

Volltextzugriff (PDF)

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer

Nature medicine, 2015-09, Vol.21 (9), p.1038-1047

2015

Volltextzugriff (PDF)

Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis

Nature communications, 2024-03, Vol.15 (1), p.2568-10, Article 2568

2024

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(60)

Sprache

Englisch
(60)

Erscheinungsjahr

n.n

Thema

Humans
(29)
Science & Technology
(29)
Life Sciences & Biomedicine
(24)
Oncology
(20)
Lung Neoplasms - Drug Therapy
(13)
Lung Neoplasms - Pathology
(10)
Lung Neoplasms - Genetics
(9)
Mutation
(9)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(7)
Female
(7)
Male
(7)
Cell Biology
(6)
Cell Line, Tumor
(6)
Lung Cancer
(6)
Middle Aged
(6)
Aged
(5)
Biochemistry & Molecular Biology
(5)
Carcinoma, Non-Small-Cell Lung - Genetics
(5)
Acquired Resistance
(4)
Animals
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib

APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas

Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC)

Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding

112OCirculating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC)

Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation

DIRECT: DNA-mutation Inventory to Refine and Enhance Cancer Treatment—A catalogue of clinically relevant somatic mutations in lung cancer

My Cancer Genome: Web-based clinical decision support for genome-directed lung cancer treatment

Characterization of novel potent and selective anaplastic lymphoma kinase (ALK) inhibitors

Abstract P3-03-03: An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer

Accurate Mass-Driven Analysis for the Characterization of Protein Phosphorylation. Study of the Human Chk2 Protein Kinase

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids

EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer

Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis

Suchergebnisse filtern